Lopinavir + Ritonavir Farmoz

Lopinavir, the active ingredient in Lopinavir + Ritonavir Farmoz, is a protease inhibitor presented as an oral tablet formulation for oral use. It is used in combination therapy to treat HIV-1 infection in adults and children. GNH USA supplies Lopinavir + Ritonavir Farmoz as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lopinavir/ritonavir is a protease inhibitor used in the management of HIV-1 infection. - Adults with HIV-1 infection: reduces viral load and improves immune function. - Children with HIV-1 infection: helps achieve viral suppression and supports growth. - Pregnant women with HIV-1 infection: part of combination therapy to lower the risk of mother‑to‑child transmission.

Lopinavir + Ritonavir may cause a range of adverse reactions.

Common Side Effects: - Diarrhea: frequent loose stools. - Nausea: feeling of sickness or urge to vomit. - Vomiting: expulsion of stomach contents. - Abdominal pain: discomfort in the stomach area. - Headache: mild to moderate head pain. - Elevated lipids: increase in cholesterol or triglycerides.

Serious or Rare Side Effects: - Hepatotoxicity: liver enzyme elevations or liver injury. - Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain. - Severe allergic reactions: rash, swelling, or anaphylaxis. - QT prolongation: potential heart rhythm disturbances. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction.

Before initiating therapy, several safety considerations are recommended. - Monitor liver function: perform baseline and periodic hepatic enzyme tests. - Assess lipid profile: watch for hyperlipidaemia and manage accordingly. - Evaluate for drug resistance: review prior antiretroviral exposure. - Avoid in patients with known hypersensitivity to lopinavir, ritonavir, or excipients. - Store at room temperature: keep in the original container, protect from moisture and heat.

Lopinavir/ritonavir interacts with several medication classes and requires careful management.

Major Interactions (Avoid): - CYP3A4 substrates such as simvastatin or lovastatin: risk of severe toxicity. - Strong CYP3A4 inducers like rifampicin: markedly reduces lopinavir exposure. - Certain antiarrhythmics (e.g., amiodarone): may cause dangerous cardiac effects.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may require INR monitoring and dose adjustment. - Oral hypoglycemics (e.g., sulfonylureas): increased risk of hypoglycaemia. - Other protease inhibitors: potential for additive toxicity and altered drug levels.